GONUTS has been updated to MW1.31 Most things seem to be working but be sure to report problems.
ECOLX:A0A1W5T566
Contents
Species (Taxon ID) | Escherichia coli. (562) | |
Gene Name(s) | cnf1 (ECO:0000313 with EMBL:ARF06329.1) | |
Protein Name(s) | Cytotoxic necrotizing factor 1 (ECO:0000313 with EMBL:ARF06329.1) | |
External Links | ||
UniProt | A0A1W5T566 | |
EMBL | KX446780 | |
GO | GO:0016021 |
Annotations
Qualifier | GO ID | GO term name | Reference | ECO ID | ECO term name | with/from | Aspect | Extension | Notes | Status |
---|---|---|---|---|---|---|---|---|---|---|
GO:2000251 |
positive regulation of actin cytoskeleton reorganization |
ECO:0006062 |
wide-field fluorescence microscopy evidence used in manual assertion |
P |
In Figure 4 they use florescence microscopy to confirm the CNF1 protein in E.coli induces changes in the organization of the actin cytoskeleton in stress fibers and membrane protrusions, which prevents cytoadherence. This is shown through the addition of CNF1 protein and other inhibitors. With the addition of CNF1 compared to the control you can see the rearrangement of the cytoskeleton but, in the presence of inhibitors along with CNF1 the modifications of rearrangement are decreased. |
complete | ||||
GO:0020035 |
cytoadherence to microvasculature, mediated by symbiont protein |
ECO:0001143 |
adhesion assay evidence used in manual assertion |
P |
In Figure 1, adhesion assays were used to determine that CNF1 decreased pRBC cytoadherence in both cell line models by at least 40 percent. This is proven by comparing the pre- and post-treatment of the CNF1 protein with the TNF-alpha activated control. In figure 1A, CNF1 is used as pre-treatment to prevent the attachment of pRBC. In figure 1B, CNF1 is used as post-treatment to reverse adherence of pRBCs to endothelial cells. |
complete | ||||
GO:0034446 |
substrate adhesion-dependent cell spreading |
ECO:0007046 |
scanning electron microscopy evidence used in manual assertion |
P |
Figure 3A is a scanning electron micrograph that shows the response of brain cells to treatment with CNF1 protein, a mutant version of the protein (CNF1 C866S), or a control (TNF-alpha). Cells treated with CNF1 had increased monolayer confluence, as CNF1 promoted cell spreading and flattening. Cells treated with CNF1 C866S or TNF-alpha had an unchanged surface morphology in comparison. |
complete | ||||
part_of |
GO:0016020 |
membrane |
ECO:0000323 |
imported automatically asserted information used in automatic assertion |
C |
Seeded From UniProt |
complete | |||
part_of |
GO:0016021 |
integral component of membrane |
ECO:0000323 |
imported automatically asserted information used in automatic assertion |
C |
Seeded From UniProt |
complete | |||
Notes
References
See Help:References for how to manage references in GONUTS.
- ↑ 1.0 1.1 1.2 Messina, V et al. (2019) The bacterial protein CNF1 as a new strategy against Plasmodium falciparum cytoadherence. PLoS ONE 14 e0213529 PubMed GONUTS page
b